There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Prophase Labs (PRPH – Research Report) and Regulus (RGLS – Research Report) with bullish sentiments.
Prophase Labs (PRPH)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Prophase Labs today and set a price target of $14.00. The company’s shares closed last Monday at $9.91.
According to TipRanks.com, Chen has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Prophase Labs with a $9.50 average price target.
See today’s best-performing stocks on TipRanks >>
Regulus (RGLS)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Regulus, with a price target of $2.00. The company’s shares closed last Monday at $0.26, close to its 52-week low of $0.16.
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Regulus is a Moderate Buy with an average price target of $2.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PRPH:
- Blackrock Investors Usurp Voting Power in Their Hands
- Nuvectis Pharma (NVCT) Receives a Buy from H.C. Wainwright
- H.C. Wainwright Sticks to Their Buy Rating for Uranium Energy (UEC)
- Rosenblatt Securities Keeps Their Hold Rating on Amazon (AMZN)
- Analysts Offer Insights on Healthcare Companies: Mustang Bio (MBIO), Cybin (CYBN) and Century Therapeutics (IPSC)
